Short peptide-based tolerogens without self-antigenic or pathogenic activity reverse autoimmune disease

Journal of Immunology

Volumn 160, Issue 10, 1998, Pages 5188-5194

  Karin, Nathan ^d   Binah, Ofer ^d   Grabie, Nir ^d   Mitchell, Dennis J ^a   Felzen, Bella ^d   Solomon, Matthew D ^a   Conlon, Paul ^c   Gaur, Amitabh ^c   Ling, Nicholas ^c   Steinman, Lawrence ^a,b  

^a STANFORD UNIVERSITY   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c NEUROCRINE BIOSCIENCES INC   (United States)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

MYELIN BASIC PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; AUTOIMMUNE DISEASE; FEMALE; IMMUNOGENICITY; MULTIPLE SCLEROSIS; NONHUMAN; PARAPLEGIA; PATHOGENESIS; PRIORITY JOURNAL; RAT; T LYMPHOCYTE;

ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMMUNE TOLERANCE; INTERFERON TYPE II; MYELIN BASIC PROTEINS; PEPTIDE FRAGMENTS; RATS; RATS, INBRED LEW; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 15144342683     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 85:299.
2. Steinman L. Escape from "horror autotoxicus": pathogenes is and treatment of autoimmune disease. Cell 80:7.
3. Hafler, D. A., M. G. Saadeh, V. K. Kuchroo, E. Milford, and L. Steinman. 1996. T cell receptor usage in human and experimental demyelinating disease. Immunol. Today 17:152.
4. Steinman, L. A. Waisman, and D. Altmann. 1995. Major T cell responses in multiple sclerosis. Mol Med. Today 1:79.
5. Martin, R., D. Jaraquemada, M. Fierlage, J. Riehert, J. Whitaker, E. O. Long, D. E. McFarlin, and H. F. McFarland. 1990. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J. Immunol. 145:540.
6. Warren, K. G., I. Catz, and L. Steinman. 1995. Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: the minimal B-cell epitope and a model of its features. Proc. Natl. Acad. Sci USA 92:11061.
7. Karin, N., D. Mitchell, S. Brock, N. Ling, and L. Steinman. 1994. Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of IFN-γ and TNF-α production. J. Exp. Med. 180:2227.
8. Ruddle, N. H., C. M. Bergman, K. M. McGrath, E. G. Lingenheld, M. L. Grunnet, S. J. Padula, and R. B. Clark. 1990. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172:1193.
9. Thornhill, M. H., S. M. Wellicome, D. L. Mahiouz, J. S. Lanchbury, A. U. Kyan, and D. O. Haskard. 1991. Tumor necrosis factor combines with IL-4 or IFN-γ to selectively enhance endothelial cell adhesiveness for T cells: the contribution of vascular cell adhesion molecule-1-dependent and -independent binding mechanisms. J. Immunol. 146:592.
10. Selmaj, K., C. S. Raine, and A. H. Cross. 1991. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann. Neurol. 30:694.
11. Powell, M. B., D. Mitchell, J. Lederman, J. Buckmeier, S. S. Zamvil, M. Graham, N. H. Ruddle, and L. Steinman. 1990. Lymphotoxin and tumor necrosis factor-α production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Int. Immunol. 2:539.
12. Kuroda, Y., and Y. Shimamoto. 1991. Human tumor necrosis factor-alpha augments experimental allergic encephalomyelitis in rats. J. Neuroimmunol 34:159.
13. Gautam, A. M., C. I. Pearson, D. E. Smilek, L. Steinman, and H. O. McDevitt. 1992. A polyalanine peptide with only five native myelin basic protein residues induces autoimmune encephalomyelitis. J. Exp. Med. 176:605.
14. Gautam, A. M., C. B. Lock, D. E. Smilek, C. I. Pearson, L. Steinman, and H. O. McDevitt. 1994. Minimum structural requirements for peptide presentation by major histocompatibility complex class II molecules: implications in induction of autoimmunity. Proc. Natl. Acad. Sci USA 91:767.
15. + T cells [see comments]. Science 271:1272.
16. + T cells [see comments]. Science 271:1276.
17. 2+ response amplitude and duration. Nature 386:855.
18. Berridge, M. J.. 1997. The AM and FM of calcium signalling. Nature 386:759.